{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:02:02Z","timestamp":1786982522959,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02099-w","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T11:04:48Z","timestamp":1742727888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term survival in a patient with ruptured advanced hepatocellular carcinoma treated with nutritional therapy combined with apatinib and camrelizumab: a case report"],"prefix":"10.1007","volume":"16","author":[{"given":"Yaohao","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqiang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"2099_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006.","journal-title":"J Natl Cancer Cent"},{"key":"2099_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology. 2018;68:723\u201350. https:\/\/doi.org\/10.1002\/hep.29913.","journal-title":"Hepatology"},{"key":"2099_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijsu.2015.05.009","volume":"20","author":"ZM Zhang","year":"2015","unstructured":"Zhang ZM, Lai ECH, Zhang C, Yu HW, Liu Z, Wan BJ, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg. 2015;20:8\u201316. https:\/\/doi.org\/10.1016\/j.ijsu.2015.05.009.","journal-title":"Int J Surg"},{"key":"2099_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/13651820410024058","volume":"7","author":"F Pons","year":"2005","unstructured":"Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35\u201341. https:\/\/doi.org\/10.1080\/13651820410024058.","journal-title":"HPB (Oxford)"},{"key":"2099_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Br\u00fa C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329\u201338. https:\/\/doi.org\/10.1055\/s-2007-1007122.","journal-title":"Semin Liver Dis"},{"key":"2099_CR6","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003\u201315: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555\u201367. https:\/\/doi.org\/10.1016\/S2214-109X(18)30127-X.","journal-title":"Lancet Glob Health"},{"key":"2099_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"key":"2099_CR8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/jhc.S462168","volume":"11","author":"YK Li","year":"2024","unstructured":"Li YK, Wu S, Wu YS, Zhang WH, Wang Y, Li YH, et al. Portal venous and hepatic arterial coefficients predict post-hepatectomy overall and recurrence-free survival in patients with hepatocellular carcinoma: a retrospective study. J Hepatocell Carcinoma. 2024;11:1389\u2013402. https:\/\/doi.org\/10.2147\/jhc.S462168.","journal-title":"J Hepatocell Carcinoma"},{"key":"2099_CR9","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1007\/s11605-018-3930-7","volume":"23","author":"W Zhang","year":"2019","unstructured":"Zhang W, Zhang Z-W, Zhang B-X, Huang Z-Y, Zhang W-G, Liang H-F, et al. Outcomes and prognostic factors of spontaneously ruptured hepatocellular carcinoma. J Gastrointest Surg. 2019;23:1788\u2013800. https:\/\/doi.org\/10.1007\/s11605-018-3930-7.","journal-title":"J Gastrointest Surg"},{"key":"2099_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jceh.2018.04.002","volume":"9","author":"SK Sahu","year":"2019","unstructured":"Sahu SK, Chawla YK, Dhiman RK, Singh V, Duseja A, Taneja S, et al. Rupture of hepatocellular carcinoma: a review of literature. J Clin Exp Hepatol. 2019;9:245\u201356. https:\/\/doi.org\/10.1016\/j.jceh.2018.04.002.","journal-title":"J Clin Exp Hepatol"},{"key":"2099_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.Ccr-18-2484","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res. 2019;25:515\u201323. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2484.","journal-title":"Clin Cancer Res"},{"key":"2099_CR12","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.clnu.2014.11.007","volume":"34","author":"K Sch\u00fctte","year":"2015","unstructured":"Sch\u00fctte K, Tippelt B, Schulz C, R\u00f6hl F-W, Feneberg A, Seidensticker R, et al. Malnutrition is a prognostic factor in patients with hepatocellular ca rcinoma (HCC). Clin Nutr. 2015;34:1122\u20137. https:\/\/doi.org\/10.1016\/j.clnu.2014.11.007.","journal-title":"Clin Nutr"},{"key":"2099_CR13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.hpb.2023.08.012","volume":"25","author":"S Omiya","year":"2023","unstructured":"Omiya S, Urade T, Komatsu S, Kido M, Kuramitsu K, Yanagimoto H, et al. Impact of GLIM criteria-based malnutrition diagnosis on outcomes follo wing liver resection for hepatocellular carcinoma. HPB (Oxford). 2023;25:1555\u201365. https:\/\/doi.org\/10.1016\/j.hpb.2023.08.012.","journal-title":"HPB (Oxford)"},{"key":"2099_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","volume":"32","author":"A Vogel","year":"2021","unstructured":"Vogel A, Martinelli E. org EGCEace, Committee EG updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32:801\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014.","journal-title":"Ann Oncol"},{"key":"2099_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","volume":"8","author":"H-D Zhu","year":"2023","unstructured":"Zhu H-D, Li H-L, Huang M-S, Yang W-Z, Yin G-W, Zhong B-Y, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8:58. https:\/\/doi.org\/10.1038\/s41392-022-01235-0.","journal-title":"Signal Transduct Target Ther"},{"key":"2099_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"Z-C Jin","year":"2024","unstructured":"Jin Z-C, Chen J-J, Zhu X-L, Duan X-H, Xin Y-J, Zhong B-Y, et al. Immune checkpoint inhibitors and anti-vascular endothelial growth fact or antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular c arcinoma (CHANCE2201): a target trial emulation study. EClinicalMedicine. 2024;72: 102622. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102622.","journal-title":"EClinicalMedicine"},{"key":"2099_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/1471-2407-10-529","volume":"10","author":"J Li","year":"2010","unstructured":"Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:529. https:\/\/doi.org\/10.1186\/1471-2407-10-529.","journal-title":"BMC Cancer"},{"key":"2099_CR18","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.3748\/wjg.v19.i28.4537","volume":"19","author":"Y-J Jin","year":"2013","unstructured":"Jin Y-J, Lee J-W, Park S-W, Lee JI, Lee DH, Kim YS, et al. Survival outcome of patients with spontaneously ruptured hepatocellular carcinoma treated surgically or by transarterial embolization. World J Gastroenterol. 2013;19:4537\u201344. https:\/\/doi.org\/10.3748\/wjg.v19.i28.4537.","journal-title":"World J Gastroenterol"},{"key":"2099_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3779\/j.issn.1009-3419.2021.101.16","volume":"24","author":"Z Xu","year":"2021","unstructured":"Xu Z, Li J. Review on the combination strategy of anti-angiogenic agents and other anti-tumor agents in advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2021;24:357\u201364. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2021.101.16.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"2099_CR20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","journal-title":"Lancet"},{"key":"2099_CR21","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1186\/s12885-022-10296-x","volume":"22","author":"R Caccialanza","year":"2022","unstructured":"Caccialanza R, Cereda E, Agustoni F, Klersy C, Casirati A, Montagna E, et al. Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling. BMC Cancer. 2022;22:1212. https:\/\/doi.org\/10.1186\/s12885-022-10296-x.","journal-title":"BMC Cancer"},{"key":"2099_CR22","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.3390\/nu15204408","volume":"15","author":"S Martinelli","year":"2023","unstructured":"Martinelli S, Lamminp\u00e4\u00e4 I, D\u00fcb\u00fc\u015f EN, Sar\u0131kaya D, Niccolai E. Synergistic strategies for gastrointestinal cancer care: unveiling the benefits of immunonutrition and microbiota modulation. Nutrients. 2023;15:4408. https:\/\/doi.org\/10.3390\/nu15204408.","journal-title":"Nutrients"},{"key":"2099_CR23","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/cncr.25709","volume":"117","author":"RA Murphy","year":"2011","unstructured":"Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, Mazurak VC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 2011;117:1775\u201382. https:\/\/doi.org\/10.1002\/cncr.25709.","journal-title":"Cancer"},{"key":"2099_CR24","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.clnu.2011.05.008","volume":"30","author":"NEP Deutz","year":"2011","unstructured":"Deutz NEP, Safar A, Schutzler S, Memelink R, Ferrando A, Spencer H, et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr. 2011;30:759\u201368. https:\/\/doi.org\/10.1016\/j.clnu.2011.05.008.","journal-title":"Clin Nutr"},{"key":"2099_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jhep.2015.02.031","volume":"63","author":"N Fujiwara","year":"2015","unstructured":"Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63:131\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.031.","journal-title":"J Hepatol"},{"key":"2099_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.cgh.2013.08.050","volume":"12","author":"T Kawaguchi","year":"2014","unstructured":"Kawaguchi T, Shiraishi K, Ito T, Suzuki K, Koreeda C, Ohtake T, et al. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12:1012-1018.e1011. https:\/\/doi.org\/10.1016\/j.cgh.2013.08.050.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"2099_CR27","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1017\/S0007114507832909","volume":"98","author":"PC Calder","year":"2007","unstructured":"Calder PC. Immunonutrition in surgical and critically ill patients. Br J Nutr. 2007;98(Suppl 1):S133-139. https:\/\/doi.org\/10.1017\/S0007114507832909.","journal-title":"Br J Nutr"},{"key":"2099_CR28","doi-asserted-by":"publisher","first-page":"7860","DOI":"10.1245\/s10434-024-15933-2","volume":"31","author":"Y Chen","year":"2024","unstructured":"Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, et al. Clinical effectiveness and safety of transarterial chemoembolization: hepatic artery infusion chemotherapy plus tyrosine kinase inhibitors with or without programmed cell death protein-1 inhibitors for unresectable hepatocellular carcinoma-a retrospective study. Ann Surg Oncol. 2024;31:7860\u20139. https:\/\/doi.org\/10.1245\/s10434-024-15933-2.","journal-title":"Ann Surg Oncol"},{"key":"2099_CR29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10620-011-1995-1","volume":"57","author":"M-S Kwak","year":"2012","unstructured":"Kwak M-S, Lee J-H, Yoon J-H, Yu SJ, Cho EJ, Jang ES, et al. Risk factors, clinical features, and prognosis of the hepatocellular carcinoma with peritoneal metastasis. Dig Dis Sci. 2012;57:813\u20139. https:\/\/doi.org\/10.1007\/s10620-011-1995-1.","journal-title":"Dig Dis Sci"},{"key":"2099_CR30","doi-asserted-by":"publisher","first-page":"1391724","DOI":"10.3389\/fonc.2024.1391724","volume":"14","author":"X Shen","year":"2024","unstructured":"Shen X, Yang J, Qian G, Sheng M, Wang Y, Li G, et al. Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol. 2024;14:1391724. https:\/\/doi.org\/10.3389\/fonc.2024.1391724.","journal-title":"Front Oncol"},{"key":"2099_CR31","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1097\/cm9.0000000000003301","volume":"137","author":"J Sun","year":"2024","unstructured":"Sun J, Li Q, Bai X, Cai J, Chen Y, Chen M, et al. Chinese expert consensus on clinical application of molecularly targeted drugs for hepatocellular carcinoma. Chin Med J (Engl). 2024;137:2630\u20132. https:\/\/doi.org\/10.1097\/cm9.0000000000003301.","journal-title":"Chin Med J (Engl)"},{"key":"2099_CR32","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1007\/s00520-020-05727-z","volume":"28","author":"BL Rapoport","year":"2020","unstructured":"Rapoport BL, Anderson R, Cooksley T. Johnson DB MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. Support Care Cancer. 2020;28:6107\u201310. https:\/\/doi.org\/10.1007\/s00520-020-05727-z.","journal-title":"Support Care Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02099-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02099-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02099-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T11:04:52Z","timestamp":1742727892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02099-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2099"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02099-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study involving human participants was reviewed and approved by the Ethics Committee of Liuzhou People's Hospital. All experimental protocols involving human data were in accordance with our institutional guidelines of the Declaration of Helsinki, and written informed consent was obtained from the study patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}